Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Marshall Wace LLP

Marshall Wace LLP boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 15,927.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 846,107 shares of the company's stock after purchasing an additional 840,828 shares during the period. Marshall Wace LLP owned about 1.42% of Twist Bioscience worth $39,319,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of TWST. Stifel Financial Corp increased its holdings in Twist Bioscience by 11.8% in the 3rd quarter. Stifel Financial Corp now owns 6,967 shares of the company's stock worth $315,000 after acquiring an additional 734 shares in the last quarter. Barclays PLC increased its stake in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock valued at $61,807,000 after purchasing an additional 26,145 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at $34,000. Finally, Franklin Resources Inc. lifted its stake in shares of Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company's stock valued at $11,756,000 after buying an additional 8,308 shares in the last quarter.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded down $1.65 during mid-day trading on Friday, reaching $36.80. The company's stock had a trading volume of 747,299 shares, compared to its average volume of 983,176. The stock has a market capitalization of $2.20 billion, a P/E ratio of -10.89 and a beta of 2.34. Twist Bioscience Co. has a 1-year low of $27.96 and a 1-year high of $60.90. The stock has a 50-day moving average of $40.57 and a two-hundred day moving average of $44.44. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the previous year, the business earned ($0.75) earnings per share. The company's revenue for the quarter was up 24.1% on a year-over-year basis. On average, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of several research analyst reports. Guggenheim set a $50.00 price objective on Twist Bioscience in a research report on Friday, March 28th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays lowered their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Finally, Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $52.80.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the sale, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paula Green sold 918 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,796 shares of company stock worth $1,077,383. 3.01% of the stock is currently owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.